184 related articles for article (PubMed ID: 31114029)
1. Metastatic melanoma and immunotherapy-related uveitis: an incidence in Northern Ireland.
Dolaghan MJ; Oladipo B; Cooke CA; McAvoy CE
Eye (Lond); 2019 Oct; 33(10):1670-1672. PubMed ID: 31114029
[No Abstract] [Full Text] [Related]
2. Bilateral anterior uveitis and unilateral facial palsy due to ipilimumab for metastatic melanoma in an individual with human leukocyte antigen DR4: A case report.
Numata S; Iwata Y; Okumura R; Arima M; Kobayashi T; Watanabe S; Suzuki K; Horiguchi M; Sugiura K
J Dermatol; 2018 Jan; 45(1):113-114. PubMed ID: 28225147
[No Abstract] [Full Text] [Related]
3. Management of Chronic Hypotony Following Bilateral Uveitis in a Patient Treated with Pembrolizumab for Cutaneous Metastatic Melanoma.
Reid G; Lorigan P; Heimann H; Hovan M
Ocul Immunol Inflamm; 2019; 27(6):1012-1015. PubMed ID: 29672247
[No Abstract] [Full Text] [Related]
4. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
[TBL] [Abstract][Full Text] [Related]
5. [Meningeal syndrome in a patient treated with a combination of immune checkpoint inhibitors for a metastatic melanoma].
Bello-Chavolla OY; Cortes-Arroyo JE; Vargas-Vazquez A; Quiroz-Compean F; Leal-Gutierrez G; Barragan-Dessavre M; Martinez-Samano JE
Rev Neurol; 2018 Oct; 67(7):279-280. PubMed ID: 30232801
[TBL] [Abstract][Full Text] [Related]
6. Case 9-2020: A 64-Year-Old Man with Shortness of Breath, Cough, and Hypoxemia.
Reynolds KL; Sullivan RJ; Fintelmann FJ; Mansour MK; England J
N Engl J Med; 2020 Mar; 382(12):1150-1159. PubMed ID: 32187473
[No Abstract] [Full Text] [Related]
7. Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma.
Lasocki A; Smith K
J Clin Neurosci; 2020 Apr; 74():240-241. PubMed ID: 31983645
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in colorectal cancer with mismatch repair deficiency.
Overman MJ
Clin Adv Hematol Oncol; 2019 May; 17(5):265-267. PubMed ID: 31188802
[No Abstract] [Full Text] [Related]
9. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma.
Alnabulsi R; Hussain A; DeAngelis D
Orbit; 2018 Oct; 37(5):381-384. PubMed ID: 29381409
[TBL] [Abstract][Full Text] [Related]
10. Development of Poliosis Following Checkpoint Inhibitor Treatment for Cutaneous Melanoma.
Ediriwickrema LS; Liu CY; Kikkawa DO; Korn BS
Ophthalmic Plast Reconstr Surg; 2019; 35(5):e121-e122. PubMed ID: 31373986
[TBL] [Abstract][Full Text] [Related]
11. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.
Chin CK; Hall S; Green C; Van Hazel G; Spagnolo D; Cheah CY
Eur J Cancer; 2019 Jul; 115():84-87. PubMed ID: 31129384
[No Abstract] [Full Text] [Related]
12. Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab.
Omodaka T; Kiniwa Y; Sato Y; Suwa M; Sato M; Yamaguchi T; Sato A; Miyake T; Okuyama R
J Dermatol; 2018 Oct; 45(10):e289-e290. PubMed ID: 29667767
[No Abstract] [Full Text] [Related]
13. Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab.
Kuwatsuka Y; Iwanaga A; Kuwatsuka S; Okubo Y; Murayama N; Ishii N; Hashimoto T; Utani A
J Dermatol; 2018 Jan; 45(1):e21-e22. PubMed ID: 28944534
[No Abstract] [Full Text] [Related]
14. Cardiotoxicity associated with immune checkpoint inhibitors in cutaneous oncology.
Tabata MM; Choi S; Hirotsu K; Kwong B; Soleymani T
J Am Acad Dermatol; 2020 Apr; 82(4):986-994. PubMed ID: 31437546
[No Abstract] [Full Text] [Related]
15. Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases: A Possible Variant of Locus Minoris Resistentiae.
Donaldson M; Owen JL; Choi JN
JAMA Dermatol; 2018 Jul; 154(7):846-847. PubMed ID: 29800007
[No Abstract] [Full Text] [Related]
16. Autoimmune Bell's Palsy Following Immunotherapy For Metastatic Melanoma: A Report of 2 Cases.
Zieman D; Frankel AE
J Immunother; 2019 Oct; 42(8):318-320. PubMed ID: 31318723
[TBL] [Abstract][Full Text] [Related]
17. Combination Ipilimumab and Nivolumab for Metastatic Melanoma Associated With Ciliochoroidal Effusion and Exudative Retinal Detachment.
Tsui E; Madu A; Belinsky I; Yannuzzi LA; Freund KB; Modi YS
JAMA Ophthalmol; 2017 Dec; 135(12):1455-1457. PubMed ID: 29145556
[No Abstract] [Full Text] [Related]
18. Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab.
Saibil SD; Bonilla L; Majeed H; Sotov V; Hogg D; Chappell MA; Cybulsky M; Butler MO
Curr Oncol; 2019 Jun; 26(3):e418-e421. PubMed ID: 31285688
[TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy.
Irwin DE; Davis B; Bell JA; Galaznik A; Garcia-Ribas I
J Comp Eff Res; 2019 Jan; 8(2):81-90. PubMed ID: 30547675
[TBL] [Abstract][Full Text] [Related]
20. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
